BioCentury
ARTICLE | Clinical News

Ganaxolone: Phase II started

February 23, 2015 8:00 AM UTC

Marinus began an open-label, U.S. Phase II trial to evaluate daily ganaxolone given as either oral liquid suspension or capsules for up to 26 weeks in about 10 girls ages 2-10 with confirmed mutations...